Table 2.
Changes in clinical parameters after administration of n-3 PUFAs
| Parameter | Before | After | P-value |
|---|---|---|---|
| BMI (kg/m2) | 28.2 ± 5.4 | 28.0 ± 5.4 | 0.700 |
| SBP (mmHg) | 141.0 ± 7.6 | 136.0 ± 11.3 | 0.113 |
| DBP (mmHg) | 74.9 ± 11.0 | 77.9 ± 11.0 | 0.334 |
| HbA1c (%) | 6.9 ± 0.5 | 7.1 ± 0.6 | 0.038 |
| FPG (mg/dL) | 132.3 ± 18.7 | 134.7 ± 25.8 | 0.664 |
| TC (mg/dL) | 171.3 ± 21.5 | 150.5 ± 16.0 | < 0.001 |
| LDL-C (mg/dL) | 90.3 ± 17.1 | 79.4 ± 11.4 | 0.003 |
| HDL-C (mg/dL) | 44.9 ± 9.5 | 45.5 ± 11.3 | 0.763 |
| TG (mg/dL) | 195.7 ± 49.9 | 128.7 ± 58.8 | < 0.001 |
| EPA/AA | 0.30 ± 0.19 | 1.30 ± 0.30 | 0.008 |
| DHA/AA | 0.75 ± 0.16 | 1.29 ± 0.32 | 0.008 |
| AST (IU/L) | 21.6 ± 6.0 | 21.8 ± 5.2 | 0.828 |
| ALT (IU/L) | 24.2 ± 6.0 | 25.4 ± 7.2 | 0.977 |
| Cre (mg/dL) | 0.81 ± 0.32 | 0.83 ± 0.36 | 0.539 |
Data represent the means ± standard deviation. P-values represent differences observed before and after administration of n-3 PUFAs. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycated hemoglobin, FPG fasting plasma glucose, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TG triglyceride, AST aspartate aminotransferase, ALT alanine aminotransferase, Cre creatinine